Literature DB >> 32838690

Letter to the Editor: Clinically Significant Hyperthyroidism and Hypothyroidism Following Exposure to Compounded Thyroid Products.

Jenny Kim1, Karen Konkel1, Ida-Lina Diak1, Shannon Glueck2, Lynda McCulley1.   

Abstract

Entities:  

Year:  2020        PMID： 32838690      PMCID： PMC7855378          DOI： 10.1089/thy.2020.0544

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  5 in total

1.  Stability and consistency of compounded oral liquid levothyroxine formulations.

Authors:  Lindsey M Meyer; Kala Stephens; Charles A Carter; William Pickard; Paul R Johnson; David H Eagerton
Journal:  J Am Pharm Assoc (2003)       Date:  2020-06-24

2.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values.

Authors:  Alexander Kratz; Maryjane Ferraro; Patrick M Sluss; Kent B Lewandrowski
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

3.  Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange.

Authors:  Kabeer K Shah; Michael M Mbughuni; Edwin A Burgstaler; Darci R Block; Jeffrey L Winters
Journal:  J Clin Apher       Date:  2017-03-20       Impact factor: 2.821

4.  Severe TSH Elevation and Pituitary Enlargement After Changing Thyroid Replacement to Compounded T4/T3 Therapy.

Authors:  Adlai L Pappy; Nelson Oyesiku; Adriana Ioachimescu
Journal:  J Investig Med High Impact Case Rep       Date:  2016-08-02

Review 5.  Thyrotoxicosis after massive triiodothyronine (LT3) overdose: a coast-to-coast case series and review.

Authors:  Zhiheng H He; Yan Li; Nitin Trivedi; Sabrina Gill; James V Hennessey
Journal:  Drugs Context       Date:  2020-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.